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Background
The most important comorbidity in renal patients is rep-
resented by cardiovascular complications, with impaired
NO production as key pathway. In premenopause, estro-
gens seem to exert protective effects on the vascular sys-
tem. This study investigates the effects of both gender and
enhanced NO/cGMP signalling on aortic remodelling in
experimental hypertensive nephropathy.
Methods
Age-matched male (M) and female (F) Wistar rats were
assigned for 18 weeks into the following groups: 1) subto-
tally nephrectomized (SNX); 2) SNX Bay 41-8543-treated;
3) SNX hydralazine-treated and 4) sham operated. Bay
41-8543 is a NO-independent stimulator of soluble guan-
ylate cyclase.
Results
SNX led to increases in systolic blood pressure, with lower
levels in F rats (F-SNX 129 ± 13 mmHg vs. M-SNX 140 ±
11 mmHg). Bay 41-8543 and hydralazine reduced blood
pressure to control levels. Aortic remodelling was charac-
terized by marked media thickening in both SNX groups,
with a more pronounced increase in M versus F (127 ± 9
vs. 108 ± 6% of control; p < 0.001). Intima-media ratio
was reduced in both uremic groups, with significant sex
differences (M-SNX 66 ± 7% vs. F-SNX 80 ± 8% of control;
p < 0.01). Furthermore, gender differences were observed
in media-to-lumen ratio as indicator of aortic hypertro-
phy. The ratio was significantly higher in SNX males only
(M-SNX 131 ± 9% vs. F-SNX 107 ± 15% of control; p <
0.001). Bay 41-8543 significantly ameliorated media
thickness (111 ± 10 vs. 127 ± 9% of control in M; 101 ± 7
vs. 108 ± 6% of control in F; p < 0.05), intima-media ratio
(85 ± 10 vs. 66 ± 7% of control in M; 91 ± 6 vs. 80 ± 8%
of control in F, p < 0.01) and media-to-lumen ratio (107
± 9 vs. 131 ± 9% of control in M; p < 0.001). Despite a
similar reduction in blood pressure, hydralazine treat-
ment did not alter aortic wall remodelling. These mor-
phological changes were accompanied by elevated
collagen I and reduced elastin protein expression at the
level of aortic media, with decreased elastin/collagen ratio
in untreated SNX groups, as marker of aortic wall stiffen-
ing. Bay 41-8543 treatment successfully prevented these
molecular alterations (collagen I protein expression: 9.4 ±
0.3 vs. 14.5 ± 1.1% in females and 9.6 ± 0.4 vs. 16.1 ±
1.0% in males), while hydralazine showed no effects. SNX
was characterized by increased extracellular matrix turno-
ver with up-regulation of MMP2 and TIMP1 genes, more
pronounced in males than in females (M-SNX 1.8 ± 0.1 vs.
F-SNX 1.1 ± 0.1 for MMP2; M-SNX 4.2 ± 0.8 vs. F-SNX 2.7
± 0.6 for TIMP1; both expressed as relative values vs. con-
trols). In the male Bay 41-8543-treated group, expression
of these genes was significantly lower (1.4 ± 0.1 MMP2-
from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications
Regensburg, Germany. 19–21 June 2009
Published: 11 August 2009
BMC Pharmacology 2009, 9(Suppl 1):P19 doi:10.1186/1471-2210-9-S1-P19
<supplement> <title> <p>4th International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/P19
© 2009 Grosz et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
BMC Pharmacology 2009, 9(Suppl 1):P19 http://www.biomedcentral.com/1471-2210/9/S1/P19Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
relative expression and 1.8 ± 0.4 TIMP1-relative expres-
sion, p < 0.05).
Conclusion
The present study shows that in a model with hyperten-
sion and impaired renal function 1) aortic hypertrophy
and remodelling is significantly more severe in male gen-
der and 2) enhancing NO/GMP signalling by Bay 41-8543
ameliorates aortic wall changes significantly and in a
blood pressure-independent manner.Page 2 of 2
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